Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7914265 | 0.83 | CYP1A2 (0.43) | CYP1A2CYP2A6UHRF1PIK3CDPIK3CA | |
| SCHEMBL23473971 | 0.81 | NOS1 (0.45) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL18791340 | 0.79 | ALDH1A1 (0.34) | PDE3BPDE3ANOS1ALDH1A1NPC1 | |
| SCHEMBL25417503 | 0.79 | CYP1A2 (0.41) | CYP1A2CYP2A6UHRF1PIK3CDPIK3CA | |
| SCHEMBL23474373 | 0.76 | NNMT (0.38) | CYP1A2HSD17B10 | |
| SCHEMBL22479200 | 0.76 | NOS3 (0.32) | NOS1 | |
| SCHEMBL25054164 | 0.76 | CYP1A2 (0.38) | CYP1A2CYP2A6UHRF1PIK3CDPIK3CA | |
| SCHEMBL2742924 | 0.73 | ALDH1A1 (0.38) | CYP2A6ALDH1A1NPC1TP53MAPT | |
| SCHEMBL14438009 | 0.73 | ALDH1A1 (0.34) | NOS1ALDH1A1NPC1TP53MAPT | |
| SCHEMBL18266963 | 0.70 | CYP1A2 (0.67) | CYP1A2CYP2A6UHRF1NOS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125376-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | 上海京新生物医药有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023102162-A1 | TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-4001277-A2 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC Immune SA (CH) | 2022-05-25 | — | — | EP | disclosed |
| EP-3426653-B1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC IMMUNE SA (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-20200299305-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC IMMUNE SA | 2020-09-24 | — | — | US | disclosed |
| US-20190071450-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC IMMUNE SA (CH) | 2019-03-07 | — | — | US | disclosed |
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2649062-B1 | BICYCLIC COMPOUNDS AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | TAKEDA PHARMACEUTICAL (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| WO-2012074126-A9 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-06 | — | — | WO | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2012074126-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | WO | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010050445-A1 | BICYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071450-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | SNCA, PARK7, NLN | CYP1A2 4547/4885CYP2A6 4848/4885UHRF1 4020/4885 |
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | CYP1A2 2432/4885CYP2A6 3139/4885UHRF1 1898/4885 |
| US-20200299305-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | SNCA, PARK7, NLN | CYP1A2 4547/4885CYP2A6 4848/4885UHRF1 4020/4885 |
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | CYP1A2 112/4885CYP2A6 426/4885UHRF1 2588/4885 |
| US-20120142714-A1 | BICYCLIC COMPOUND | ACACA, ACACB, FABP4 | CYP1A2 1092/4885CYP2A6 1617/4885UHRF1 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.